Caister Academic Press

NS3 Protease Non-covalent Inhibitors

Brad O. Buckman, Karl Kossen, John B. Nicholas and Scott D. Seiwert
from: Hepatitis C: Antiviral Drug Discovery and Development (Edited by: Seng-Lai Tan and Yupeng He). Caister Academic Press, U.K. (2011)

Abstract

Progress is rapidly being made to improve the standard of care for chronic hepatitis C (HCV), which currently requires long durations of weekly pegylated interferon (peg-IFN) injections in combination with twice daily orally administered ribavirin (RBV). More effective future treatments are likely to include direct acting antiviral agents (DAAs). Several small, orally active non-covalent peptidomimetic inhibitors of NS3/4A protease have demonstrated potent reduction of HCV RNA and promising safety profiles in HCV infected patients. These agents may represent important components of future therapies. Here, the discovery, preclinical and clinical characteristics of these inhibitors are described read more ...
Access full text
Related articles ...